Biosign Receives Reimbursement Approval from NexgenRx

TORONTO, March 17, 2010 - Biosign Technologies Inc. (CNSX: BIO) (the "Company" or "Biosign") today
announced it has received notification that NexgenRx (TSX-V:NXG) will
include Biosign's UFIT(R) device and services into their Benefits Plans for
reimbursement according to regulatory clearances in the relevant
jurisdiction.

Ronald C. Louks, President & CEO of NexgenRx, said: "We see diabetic
plan members and their dependents migrating to this technology very quickly
as they lessen their dependency on the current invasive monitoring devices.
That alone is reason enough. However, when you factor in the fractionally
lower cost associated with the Biosign monthly monitoring charges, compared
to the cost of the consumable strips that plan sponsors are reimbursing
through health plans, this becomes even more compelling."

UFIT is Biosign's system for online delivery of health monitoring
services to individuals. All services, including blood pressure and blood
glucose testing, rely on digital representations of the pulse taken at
the wrist through an inflatable cuff by a portable device connected to a
computer. The noninvasive, multifunctional monitor brings an unprecedented
blend of convenience and performance to self-testing in terms of quality,
access, and cost.

John Anders SVP, Business Development at Biosign, stated: "The market
strength of NexgenRx is derived from combining industry leading technology
and clinical expertise to deliver better medical outcomes at lower costs.
We are very pleased to see that NexgenRx is supportive of our offering as
it fits perfectly into their customer value proposition."

About Biosign Technologies Inc.

Biosign provides biomedical systems. Key applications include
intelligent systems for noninvasive monitoring of common health risks
associated with blood pressure, glucose, medication. The core technology
combines measurement, analysis, and rapid knowledge formation to support
health monitoring across global markets. The UFIT(R) medical device
technology powers quality data collection and analytics for clinical
diagnostics, self-care, wellness, disease state evaluation & management,
and remote patient monitoring. For more information on Biosign please
visit www.biosign.com.

About NexgenRx

NexgenRx is a growing health benefits management company engaged in
the design, management and administration of health benefit plans offered
by employers and other plan sponsors for the benefit of their employees
and plan members. More information on NexgenRx can be found
at www.nexgenrx.com.

The CNSX has neither approved nor disapproved the contents of this
press release.

For further information: Radu Leca, President & CEO, Biosign
Technologies Inc., Phone: +1(416)218-9800 ext. 234,
Email: ceo@biosign.com.

For further information: Radu Leca, President & CEO, Biosign Technologies Inc., Phone: +1(416)218-9800 ext. 234, Email: ceo at biosign.com.